We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Femoral Remodeling Following Total Hip Arthroplasty With OMNI Apex Modular™ and OMNI Apex ARC™ Stem Compared to Competitive Designs

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01359540
Recruitment Status : Active, not recruiting
First Posted : May 24, 2011
Last Update Posted : December 13, 2017
Information provided by (Responsible Party):
David F. Scott, MD, Spokane Joint Replacement Center

Brief Summary:
This study compares the change in bone density which occurs after hip replacement with different femoral stem devices.

Condition or disease Intervention/treatment
Osteoarthritis, Hip Device: OMNI Apex Modular™ Hip Device Device: OMNI Apex ARC™ Hip Device

Study Type : Observational
Actual Enrollment : 73 participants
Observational Model: Case-Control
Time Perspective: Prospective
Official Title: A Dual Energy X-Ray Absorptiometry (DXA) Evaluation Of Bone Density Changes After Hip Replacement. Performance Of The OMNI Apex Modular™ Hip Stem And The OMNI Apex ARC™ Hip Stem In Primary Total Hip Arthroplasty, Five-Year Clinical And DXA Analysis
Actual Study Start Date : November 2009
Estimated Primary Completion Date : November 2019
Estimated Study Completion Date : November 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Bone Density
U.S. FDA Resources

Group/Cohort Intervention/treatment
APEX Modular
APEX Modular Stem group
Device: OMNI Apex Modular™ Hip Device
ARC Stem
ARC Stem group
Device: OMNI Apex ARC™ Hip Device

Primary Outcome Measures :
  1. Femoral bone mineral density [ Time Frame: Baseline, 6 weeks, 6 months, 1, 2, 3, 4, and 5 years post-operative ]
    Change in bone mineral density (BMD) as measured by DXA imaging.

Secondary Outcome Measures :
  1. Harris Hip Score (HHS) [ Time Frame: Pre-operative, 6 weeks, 6 months, 1, 2, 3, 4, and 5 years post-operative ]
    Hip functional outcomes will be assessed using the Harris Hip Score.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   20 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Adult patients undergoing elective total hip arthroplasty

Inclusion Criteria:

  • Minimum age 20 years, maximum age 80 years
  • Osteoarthritis of the hip
  • Elective THA
  • Signed Informed Consent

Exclusion Criteria:

  • Osteoporosis
  • Revisions
  • Clinically obese (>40 body mass index [BMI])
  • Femoral dysplasia
  • Trochanteric osteotomy
  • Inflammatory arthritis
  • Breast-feeding, pregnancy, or women of childbearing potential without documentation of a negative pregnancy test and not utilizing contraception
  • Patients with a history of having taken or currently taking bisphosphonates, PTH, fluoride therapy or strontium ranelate or patients taking other chronic medications that in the investigator's opinion are known to affect bone mineral density in a substantial way
  • Patients with severe medical condition(s) that in the view of the investigator prohibits participation in the study
  • Use of other investigational agent in the last 30 days
  • Unable to sign Informed Consent

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01359540

United States, Washington
Spokane Joint Replacement Center
Spokane, Washington, United States, 99218
Sponsors and Collaborators
Spokane Joint Replacement Center
Principal Investigator: David F Scott, MD Spokane Joint Replacement Center

Responsible Party: David F. Scott, MD, Principle Investigator, Spokane Joint Replacement Center
ClinicalTrials.gov Identifier: NCT01359540     History of Changes
Other Study ID Numbers: SJRC-OMNH
First Posted: May 24, 2011    Key Record Dates
Last Update Posted: December 13, 2017
Last Verified: December 2017

Keywords provided by David F. Scott, MD, Spokane Joint Replacement Center:
Total Hip Arthroplasty
Bone Loss
Femoral Remodeling
Bone mineral density
Dual Energy X-Ray Absorptiometry

Additional relevant MeSH terms:
Osteoarthritis, Hip
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases